{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:05:25Z","timestamp":1793124325984,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":2540,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1093\/annonc\/mds172","type":"journal-article","created":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T02:27:06Z","timestamp":1343788026000},"page":"3104-3110","source":"Crossref","is-referenced-by-count":42,"title":["Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"C.F.","family":"Verschraegen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Czok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.Y.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Rutledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds172_bb0010","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11912-001-0016-5","article-title":"Liposomal encapsulated anthracyclines: new therapeutic horizons","volume":"3","author":"Muggia","year":"2001","journal-title":"Curr Oncol Rep"},{"key":"10.1093\/annonc\/mds172_bb0015","first-page":"397","article-title":"Antivascular and antitumor activities of liposome-associated drugs","volume":"24","author":"Straubinger","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mds172_bb0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrc2346","article-title":"Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer","volume":"8","author":"Jain","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mds172_bb0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","article-title":"Advantages of liposomal delivery systems for anthracyclines","volume":"31","author":"Allen","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0030","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/1097-0142(20010101)91:1<90::AID-CNCR12>3.0.CO;2-A","article-title":"Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome","volume":"91","author":"Safra","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds172_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mds172_bb0045","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0050","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/153303460500400408","article-title":"Nanotechnology-based drug delivery for cancer","volume":"4","author":"Jain","year":"2005","journal-title":"Technol Cancer Res Treat"},{"key":"10.1093\/annonc\/mds172_bb0060","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-03-0787","article-title":"Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer","volume":"10","author":"Rustin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds172_bb0065","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2010.01.040","article-title":"Assessment of tumor response as a surrogate endpoint of survival in recurrent\/platinum-resistant ovarian carcinoma: a gynecologic Oncology Group study","volume":"117","author":"Rose","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mds172_bb0070","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds172_bb0075","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or Fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.6004\/jnccn.2011.0024","article-title":"Is the battle over bevacizumab coverage looming?","volume":"9","author":"Larkin","year":"2011","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1093\/annonc\/mds172_bb0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1200\/JCO.2010.32.0275","article-title":"Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions","volume":"29","author":"Ocana","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0090","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2007.06.004","article-title":"Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening","volume":"107","author":"Simpkins","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mds172_bb0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mds172_bb0100","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds172_bb0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0110","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.5009","article-title":"A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma","volume":"28","author":"Tillmanns","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0115","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1200\/JCO.2005.16.139","article-title":"Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas","volume":"23","author":"D'Adamo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2009.08.004","article-title":"Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer","volume":"73","author":"Pignata","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mds172_bb0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2011.04.046","article-title":"Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers","volume":"122","author":"Kudoh","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mds172_bb0130","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0135","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds172_bb0140","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/12\/3104\/13787235\/mds172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T19:53:30Z","timestamp":1625169210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419374824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0923753419374824"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds172","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}